Your browser doesn't support javascript.
loading
Omalizumab and allergen immunotherapy for respiratory allergies: A mini-review from the Allergen-Immunotherapy Committee of the Italian Society of Pediatric Allergy and Immunology (SIAIP).
De Filippo, Maria; Votto, Martina; Caminiti, Lucia; Carella, Francesco; Castro, Giovanna De; Landi, Massimo; Olcese, Roberta; Panasiti, Ilenia; Vernich, Mario; Barberi, Salvatore; Ciprandi, Giorgio; Marseglia, Gian Luigi.
Afiliação
  • De Filippo M; Department of Clinical, Surgical, Diagnostic, and Pediatric Sciences, University of Pavia, Pavia, Italy.
  • Votto M; Pediatric Clinic, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
  • Caminiti L; Department of Clinical, Surgical, Diagnostic, and Pediatric Sciences, University of Pavia, Pavia, Italy.
  • Carella F; Pediatric Clinic, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy; martinavotto@gmail.com.
  • Castro G; Department of Pediatrics, Allergy Unit, University of Messina, Messina, Italy.
  • Landi M; Pediatric Unit, Azienza Ospedaliera Universitaria Policlinico Giovanni XXIII, Bari, Italy.
  • Olcese R; Department of Pediatrics, Sapienza University of Rome, Rome, Italy.
  • Panasiti I; Pediatric National Healthcare System, Turin, Italy - Istituto di Biomedicina e Immunologia molecolare, Italian National Research Council, Palermo, Italy; Department of Biomedicine, Institute for Biomedical Research and Innovation, National Research Council, Palermo, Italy.
  • Vernich M; Department of Pediatrics, Allergy Center, Istituto Giannina Gaslini, Genoa, Italy.
  • Barberi S; Department of Pediatrics, Allergy Unit, University of Messina, Messina, Italy.
  • Ciprandi G; Pediatric Unit, ASST-Rhodense, RHO, Milan, Italy.
  • Marseglia GL; Pediatric Unit, ASST-Rhodense, RHO, Milan, Italy.
Allergol Immunopathol (Madr) ; 50(6): 47-52, 2022.
Article em En | MEDLINE | ID: mdl-36335444
ABSTRACT
Although currently approved to treat severe asthma and chronic spontaneous urticaria, omalizumab has also been an effective and safe add-on treatment for other allergic diseases. Namely, omalizumab has been proposed to be used as add-on therapy in patients with allergic rhinitis and asthma and undergoing specific allergen immunotherapy (AIT). AIT is the only treatment that modifies the natural history of IgE-mediated diseases. This brief review summarizes the available evidence and controversies on the efficacy and safety of omalizumab combined with specific AIT.
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Asma / Rinite Alérgica Limite: Child / Humans Idioma: En Revista: Allergol Immunopathol (Madr) Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Itália
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Asma / Rinite Alérgica Limite: Child / Humans Idioma: En Revista: Allergol Immunopathol (Madr) Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Itália